KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

Tegileridine for moderate-to-severe acute pain following abdominal surgery: A randomized, double-blind, phase 3 clinical trial.

Tingting Wang, Yafeng Wang, Haihui Xie, Zhilin Wu, Shuchun Yu, Yangwen Ou, Mingjun Xu, Wanwei Jiang, Liang Ge, Ju Gao, Qiang Wang, Hexin Gao, Yanjuan Huang, Ping Zhao, Yonghao Yu, He Huang, Jinghua Ren, Zhengyuan Xia, Jiaqiang Zhang, Jianbo Yu, Xiangdong Chen

Cell Rep Med 6(12) 102477

PMID41365300
PMCIDPMC12765830
DOI10.1016/j.xcrm.2025.102477
发表日期2025-12-09
入排依据:未发现恶性肿瘤人群证据。
疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 3 张 PMC Figure,均未识别为 KM 图:Figure 1:AI 判定为 other;Figure 1:CONSORT/入组流程图;Figure 2:非 KM 图。
摘要

摘要

Tegileridine is a biased μ-opioid receptor agonist that selectively activates the G protein pathway, designed to provide analgesia with fewer opioid-related adverse effects. In this phase 3 study, 526 patients with postoperative pain after abdominal surgery were randomized and received placebo, tegileridine at 0.75 mg, tegileridine at 1.0 mg, or morphine. For the primary outcome of effective analgesia, the mean (SD) summed pain intensity difference at rest over the first 24 h from time 0 (SPID24) scores are -61.15 (28.25) and -68.98 (30.33) for the 0.5 and 0.75 mg doses of tegileridine, respectively, compared with -49.63 (29.35) in the placebo group (all p < 0.001) and -71.16 (34.76) in the morphine group. The total pain relief scores (mean [SD]) at 24 h were 58.76 (21.79) with 0.75 mg tegileridine and 61.95 (18.94) with 1.0 mg tegileridine, compared with 47.56 (21.00) with placebo and 59.09 (19.34) with morphine. In summary, tegileridine provides effective analgesia that was significantly superior to placebo and comparable to morphine.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(3,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Figure 1无图注
非 KM Figure
Figure 1CONSORT flow diagram One participant allocated to the placebo group did not receive the study medication due to investigation decision. The investigator deemed the participant ineligible to continue in the study because the Fridericia-corrected QT (QTC f ) interval was 500 ms. One participant allocated to the 1.0 mg tegileridine group decided to withdraw from the study and did not receive the study medication.
非 KM Figure
Figure 2Usage of rescue medication (A) The proportion of participants who did not receive rescue medications in the first 24 h after loading dose administration. The data are presented as percentage (95% CI) for each group and for the differences between groups. Comparisons between groups were conducted using Fisher’s exact test. All p values were nominal. (B) Kaplan-Meier plot of first use of rescue medication. Comparisons between groups were conducted using log rank. A participant who used rescue medication at 24 h and 5 min is not shown in the figure.
非 KM Figure